Drug Trial Radar · NCT02878603
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Oct 6, 2016
Primary completion
Oct 23, 2020
Study completion Oct 23, 2020
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).
Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
Interventions
CaplacizumabBiological
Standard of CareOther
• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related EventsTime frame: From Baseline up to 36 months
- Number of Acquired Thrombotic Thrombocytopenic Purpura-related EventsTime frame: From Baseline up to 36 months
- Time to First Acquired Thrombotic Thrombocytopenic Purpura-related EventsTime frame: From Baseline up to 36 months
- Number of Participants With aTTP Related Deaths Reported During the StudyTime frame: From Baseline up to 36 months
- Percentage of Participants With Recurrence of Disease (aTTP)Time frame: From Baseline up to 36 months
- Number of Disease (aTTP) Recurrence Reported During the StudyTime frame: From Baseline up to 36 months
- Time to Recurrence of Disease (aTTP)Time frame: From Baseline up to 36 months
- Percentage of Participants With Major Thromboembolic Events Including Thrombotic Thrombocytopenic Purpura (TTP)Time frame: From Baseline up to 36 months
- Number of Major Thromboembolic Events Including Thrombotic Thrombocytopenic PurpuraTime frame: From Baseline up to 36 months
- Time to First Major Thromboembolic EventTime frame: From Baseline up to 36 months
- Cognitive Function: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Absolute Scores at Baseline, 36 Months Follow-up Visit, and Change From Baseline in RBANS Total Score at 36 Months Follow-up VisitTime frame: Baseline, 36 Months follow-up visit
- Health-Related Quality of Life (HRQoL): Change From Baseline in Headache Impact Test (HIT-6) Total Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire (SF-36) Health Survey - Physical Functioning Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Role Functioning/Physical Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Role Functioning/Emotional Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Energy/Fatigue Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Emotional Well-being Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Social Functioning Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Pain Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - General Health Domain Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Health-Related Quality of Life: Change From Baseline in 36-Item Short Form Questionnaire Health Survey - Change in Health Status Scores at Month 12, 24, and 36 Follow-up VisitsTime frame: Baseline, Month 12, 24, and 36 Follow-up visits
- Percentage of Participants With Drug-induced Treatment-emergent (TE) Anti-drug Antibodies (ADA) Positive ResponseTime frame: From Baseline up to 36 months
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Baseline up to 36 months
Locations
45 sites in 13 countries. Site status is shown where the registry gives one.
Investigator site
St Louis, Missouri
Investigator site
Valhalla, New York
Investigator Site
Durham, North Carolina
Investigator Site
Columbus, Ohio
Investigator Site
Oklahoma City, Oklahoma
Investigator site
Pittsburgh, Pennsylvania
Investigator Site
Charleston, South Carolina
Investigator site
Greenville, South Carolina
Investigator site
Vienna, Austria
Investigator site
Antwerp, Belgium
Investigator site
Brussels, Belgium
Investigator site
La Louvière, Belgium
Investigator site
Leuven, Belgium
Investigator Site
Halifax, Canada
Investigator Site
Québec, Canada
Investigator Site
Toronto, Canada
Investigator Site
Brno, Czechia
Investigator Site
Olomouc, Czechia
Investigator site
Caen, France
Investigator site
Lille, France
Investigator site
Marseille, France
Investigator site 1
Paris, France
Investigator site 2
Paris, France
Investigator Site
Budapest, Hungary
Investigator Site
Debrecen, Hungary
Investigator Site
Haifa, Israel
Investigator Site
Jerusalem Region, Israel
Investigator Site
Nahariya, Israel
Investigator Site
Catania, Italy
Investigator Site
Milan, Italy
Investigator site
Pesaro, Italy
Investigator Site
Rome, Italy
Investigator Site
Vicenza, Italy
Investigator Site 1
Barcelona, Spain
Investigator Site 2
Barcelona, Spain
Investigator site
Seville, Spain
Investigator Site 2
Valencia, Spain
Investyigator Site 1
Valencia, Spain
Investigator site
Bern, Switzerland
Investigator site
Ankara, Turkey (Türkiye)
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.